Literature DB >> 28703000

druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico.

Artur Kadurin1,2,3, Sergey Nikolenko4,2,3, Kuzma Khrabrov5, Alex Aliper1, Alex Zhavoronkov1,6,7.   

Abstract

Deep generative adversarial networks (GANs) are the emerging technology in drug discovery and biomarker development. In our recent work, we demonstrated a proof-of-concept of implementing deep generative adversarial autoencoder (AAE) to identify new molecular fingerprints with predefined anticancer properties. Another popular generative model is the variational autoencoder (VAE), which is based on deep neural architectures. In this work, we developed an advanced AAE model for molecular feature extraction problems, and demonstrated its advantages compared to VAE in terms of (a) adjustability in generating molecular fingerprints; (b) capacity of processing very large molecular data sets; and (c) efficiency in unsupervised pretraining for regression model. Our results suggest that the proposed AAE model significantly enhances the capacity and efficiency of development of the new molecules with specific anticancer properties using the deep generative models.

Entities:  

Keywords:  adversarial autoencoder; deep learning; drug discovery; generative adversarial network; variational autoencoder

Mesh:

Year:  2017        PMID: 28703000     DOI: 10.1021/acs.molpharmaceut.7b00346

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  62 in total

Review 1.  Insights into Computational Drug Repurposing for Neurodegenerative Disease.

Authors:  Manish D Paranjpe; Alice Taubes; Marina Sirota
Journal:  Trends Pharmacol Sci       Date:  2019-07-17       Impact factor: 14.819

Review 2.  Generative chemistry: drug discovery with deep learning generative models.

Authors:  Yuemin Bian; Xiang-Qun Xie
Journal:  J Mol Model       Date:  2021-02-04       Impact factor: 1.810

Review 3.  Applications of machine learning in drug discovery and development.

Authors:  Jessica Vamathevan; Dominic Clark; Paul Czodrowski; Ian Dunham; Edgardo Ferran; George Lee; Bin Li; Anant Madabhushi; Parantu Shah; Michaela Spitzer; Shanrong Zhao
Journal:  Nat Rev Drug Discov       Date:  2019-06       Impact factor: 84.694

4.  Generative network complex (GNC) for drug discovery.

Authors:  Christopher Grow; Kaifu Gao; Duc Duy Nguyen; Guo-Wei Wei
Journal:  Commun Inf Syst       Date:  2019

Review 5.  Deep learning in pharmacogenomics: from gene regulation to patient stratification.

Authors:  Alexandr A Kalinin; Gerald A Higgins; Narathip Reamaroon; Sayedmohammadreza Soroushmehr; Ari Allyn-Feuer; Ivo D Dinov; Kayvan Najarian; Brian D Athey
Journal:  Pharmacogenomics       Date:  2018-04-26       Impact factor: 2.533

6.  DeepScreening: a deep learning-based screening web server for accelerating drug discovery.

Authors:  Zhihong Liu; Jiewen Du; Jiansong Fang; Yulong Yin; Guohuan Xu; Liwei Xie
Journal:  Database (Oxford)       Date:  2019-01-01       Impact factor: 3.451

7.  Energy refinement and analysis of structures in the QM9 database via a highly accurate quantum chemical method.

Authors:  Hyungjun Kim; Ji Young Park; Sunghwan Choi
Journal:  Sci Data       Date:  2019-07-03       Impact factor: 6.444

8.  Extracting a biologically relevant latent space from cancer transcriptomes with variational autoencoders.

Authors:  Gregory P Way; Casey S Greene
Journal:  Pac Symp Biocomput       Date:  2018

Review 9.  Machine learning in chemoinformatics and drug discovery.

Authors:  Yu-Chen Lo; Stefano E Rensi; Wen Torng; Russ B Altman
Journal:  Drug Discov Today       Date:  2018-05-08       Impact factor: 7.851

Review 10.  Artificial Intelligence for Drug Toxicity and Safety.

Authors:  Anna O Basile; Alexandre Yahi; Nicholas P Tatonetti
Journal:  Trends Pharmacol Sci       Date:  2019-08-02       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.